LimmaTech Biologics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
55
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$780M
LimmaTech Biologics General Information
Description
Operator of a clinical-stage biopharmaceutical firm intended to focus on the prevention of life-threatening diseases. The company specializes in the research, development, and manufacture of bioconjugate vaccines using glycoengineering, protein glycosylation, and in vivo enzyme-based method that alleviates the issues associated with the chemical conjugation process and helps in the advancement of vaccines for multiple pathogens, enabling healthcare sectors to develop inoculation efficiently and reducing the time and cost.
Contact Information
Website
www.lmtbio.com(Operating Subsidiary)
Corporate Office
- Grabenstrasse 3
- 8952 Schlieren
- Switzerland
Corporate Office
- Grabenstrasse 3
- 8952 Schlieren
- Switzerland
LimmaTech Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 31-Jul-2026 | $780M | Completed | Clinical Trials - Phase 1 | ||
| 5. Grant | 18-Feb-2025 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series A) | 01-Feb-2024 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 2. Grant | 01-Jul-2020 | $841K | $168K | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 01-Oct-2017 | $168K | $168K | Completed | Pre-Clinical Trials |
LimmaTech Biologics Patents
LimmaTech Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025239851-A1 | Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof | Pending | 22-Mar-2024 | ||
| WO-2025196270-A1 | Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof | Pending | 22-Mar-2024 | ||
| AU-2025207078-A1 | Formulations for staphylococcus aureus vaccine | Pending | 12-Jan-2024 | ||
| WO-2025149609-A1 | Formulations for staphylococcus aureus vaccine | Inactive | 12-Jan-2024 | ||
| AU-2021342346-A1 | Fab sialylation of antibodies | Inactive | 14-Sep-2020 | C07K16/241 |
LimmaTech Biologics Signals
LimmaTech Biologics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AXA Investment Managers | Asset Manager | Minority | ||
| Adjuvant Capital | Impact Investing | Minority | ||
| CARB-X | University | Minority | ||
| INCATE | Accelerator/Incubator | |||
| Innosuisse | Government |
LimmaTech Biologics FAQs
-
When was LimmaTech Biologics founded?
LimmaTech Biologics was founded in 2015.
-
Where is LimmaTech Biologics headquartered?
LimmaTech Biologics is headquartered in Schlieren, Switzerland.
-
What is the size of LimmaTech Biologics?
LimmaTech Biologics has 55 total employees.
-
What industry is LimmaTech Biologics in?
LimmaTech Biologics’s primary industry is Biotechnology.
-
Is LimmaTech Biologics a private or public company?
LimmaTech Biologics is a Private company.
-
What is the current valuation of LimmaTech Biologics?
The current valuation of LimmaTech Biologics is .
-
What is LimmaTech Biologics’s current revenue?
The current revenue for LimmaTech Biologics is .
-
How much funding has LimmaTech Biologics raised over time?
LimmaTech Biologics has raised $40.2M.
-
Who are LimmaTech Biologics’s investors?
AXA Investment Managers, Adjuvant Capital, CARB-X, INCATE, and Innosuisse are 5 of 8 investors who have invested in LimmaTech Biologics.
-
When was LimmaTech Biologics acquired?
LimmaTech Biologics was acquired on 31-Jul-2026.
-
Who acquired LimmaTech Biologics?
LimmaTech Biologics was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process